Inivata Highlights New Clinical Data on the InVision(TM) ctDNA Liquid Biopsy Platform
in advanced NSCLC at ASCO 2017 Annual Meeting
Study shows InVision to be more sensitive than ddPCR and detects
competing resistance mutations
Research Triangle Park, NC and Cambridge, UK, 1 June, 2017 — Inivata, a global clinical cancer genomics monitoring company employing a revolutionary approach to circulating tumor DNA (‘ctDNA’) analysis to improve personalized healthcare in oncology, today announces new clinical data, from a collaboration with Dana-Farber Cancer Institute, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
In this retrospective, blinded validation study in patients with non-small cell lung cancer (NSCLC), InVision ctDNA liquid biopsy analysis was more sensitive than droplet digital PCR (ddPCR), assessing ctDNA with high specificity and quantitative concordance. In a subset of cases, serial use of InVision was able to detect the emergence of competing resistance mutations, creating an opportunity for the study of osimertinib-based targeted therapy combinations to be monitored in patients with NSCLC.
The data will be presented by Dr Nicolas Marie Guibert from Dr Geoffrey Oxnard’s group at Dana-Farber Cancer Institute in the poster session Tumor Biology on Saturday 3 June, 13:45 – 16:45: Early detection of competing resistance mutations using plasma next-generation sequencing (NGS) in patients (pts) with EGFR-mutant NSCLC treated with osimertinib (Abstract No: 11529).
Commenting on the data, Geoffrey Oxnard, MD, thoracic oncologist and lung cancer researcher at Dana-Farber Cancer Institute, said, “We are excited about the potential for plasma next-generation sequencing to identify emerging resistance mutations on EGFR targeted therapy, suggesting a possible future role as a monitoring assay to help guide the treatment of resistance.”
Clive Morris, Chief Medical Officer of Inivata, said, “This study adds to the growing evidence supporting the excellent clinical sensitivity and specificity of our InVision ctDNA panel. Our efforts are now extending into multiple studies that will help demonstrate the clinical utility of the test in different cancer settings, including clinical monitoring.”
About Inivata
Inivata, a clinical cancer genomics monitoring company, is employing the precision of ctDNA analysis to improve personalized healthcare in oncology. Using a simple blood test, ctDNA analysis is a new tool for oncologists to detect cancer, stratify patients, and assess individual response to treatment. Inivata’s proprietary platform is based on pioneering research from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge. Inivata’s InVisionTM ctDNA assay provides a highly sensitive analysis of a highly-select gene panel to identify actionable mutations for oncologists to treat their patients optimally. In 2016, Inivata opened a CLIA lab in Research Triangle Park, NC and launched a large-scale, prospective clinical validation study of the Company’s ctDNA analysis in lung cancer. For more information and a full listing of investors, please go to www.inivata.com. Follow us on Twitter @Inivata.
Media Contacts:
Consilium Strategic Communications
Chris Gardner/Laura Thornton/ Rosie Phillips
inivata@consilium-comms.com
+44 (0)20 3709 5700
Inivata
Karen Chandler-Smith
karen.chandler-smith@inivata.com
+44 (0)7900 430235
